Florida International University College of Medicine, Jackson North Medical Center, 100 NW 170th Street Suite 410, North Miami Beach, FL 33169, USA.
Eur J Nucl Med Mol Imaging. 2011 Jul;38(7):1289-95. doi: 10.1007/s00259-011-1758-4. Epub 2011 Apr 2.
Functional tumor volume (FTV) and total lesion glycolysis (TLG) are measures of metabolic activity of tumors determined by fluorodeoxyglucose (FDG) positron emission tomography (PET)/CT images. These parameters could potentially have clinical value in response to treatment evaluation and disease prognostication. The objectives of this study were to investigate the relationship between functional tumor parameters (FTV and TLG) and clinical outcomes in patients with colorectal cancer liver metastases (CRCLM) undergoing (90)Y-resin microsphere selective internal radiation therapy (SIRT) (SIR-Spheres®, Sirtex Medical Limited, Lane Cove, NSW, Australia).
FDG PET/CT studies of 20 patients with unresectable CRCLM who underwent (90)Y SIRT under a phase II clinical trial were analyzed. FTV and TLG were calculated using PET VCAR (GE Healthcare, Milwaukee, WI, USA) on pretreatment and 4-week posttreatment scans. The effects of pretreatment and posttreatment functional tumor activity on patient survival were evaluated using Kaplan-Meier survival curves.
The median survival in the study group was 14.8 months (range 2.0-27.7 months). The median survival for patients with pretreatment FTV values of above and below 200 cc were 11.2 and 26.9 months, respectively (p < 0.05). The median survival for patients with 4-week posttreatment FTV values of above and below 30 cc were 10.9 and 26.9 months, respectively (p < 0.05). The median survival for patients with pretreatment TLG values of above and below 600 g were 11.2 and 26.9 months, respectively (p < 0.05). The median survival for patients with 4-week posttreatment TLG values of above and below 100 g were 10.9 and 26.9 months, respectively (p < 0.05).
Pretreatment and posttreatment FTV and TLG showed very strong association with survival. These values can be useful quantitative criteria for patient selection and disease prognostication when (90)Y SIRT is contemplated in patients with CRCLM.
氟脱氧葡萄糖(FDG)正电子发射断层扫描(PET)/CT 图像确定的功能肿瘤体积(FTV)和总病变糖酵解(TLG)是肿瘤代谢活性的测量指标。这些参数在评估治疗反应和疾病预后方面可能具有临床价值。本研究的目的是研究在接受(90)Y 树脂微球选择性内放射治疗(SIRT)(SIR-Spheres ® ,Sirtex Medical Limited,Lane Cove,NSW,澳大利亚)的结直肠癌肝转移(CRCLM)患者中,功能肿瘤参数(FTV 和 TLG)与临床结局之间的关系。
对 20 例接受(90)Y SIRT 的不可切除 CRCLM 患者的 FDG PET/CT 研究进行了分析。在治疗前和治疗后 4 周的扫描中使用 PET VCAR(GE Healthcare,Milwaukee,WI,USA)计算 FTV 和 TLG。使用 Kaplan-Meier 生存曲线评估治疗前和治疗后功能肿瘤活性对患者生存的影响。
研究组的中位生存时间为 14.8 个月(范围 2.0-27.7 个月)。治疗前 FTV 值大于和小于 200 cc 的患者的中位生存时间分别为 11.2 和 26.9 个月(p<0.05)。治疗后 4 周 FTV 值大于和小于 30 cc 的患者的中位生存时间分别为 10.9 和 26.9 个月(p<0.05)。治疗前 TLG 值大于和小于 600 g 的患者的中位生存时间分别为 11.2 和 26.9 个月(p<0.05)。治疗后 4 周 TLG 值大于和小于 100 g 的患者的中位生存时间分别为 10.9 和 26.9 个月(p<0.05)。
治疗前和治疗后 FTV 和 TLG 与生存有很强的相关性。当考虑对 CRCLM 患者进行(90)Y SIRT 治疗时,这些值可作为患者选择和疾病预后的有用定量标准。